Nutex Health Q2 2024 GAAP EPS $(0.07) Beats $(0.29) Estimate, Sales $76.08M Beat $68.20M Estimate
Portfolio Pulse from Benzinga Newsdesk
Nutex Health (NASDAQ:NUTX) reported Q2 2024 GAAP EPS of $(0.07), significantly beating the analyst estimate of $(0.29). The company also reported sales of $76.08 million, surpassing the $68.20 million estimate and marking a 29.12% increase from the same period last year.
August 08, 2024 | 9:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nutex Health reported better-than-expected Q2 2024 results with a GAAP EPS of $(0.07) beating the $(0.29) estimate and sales of $76.08 million surpassing the $68.20 million estimate. This represents a 29.12% increase in sales from the same period last year.
The significant beat on both EPS and sales estimates, along with a notable year-over-year sales increase, is likely to positively impact Nutex Health's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100